These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15852403)

  • 41. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity.
    Dodge JC; Haidet AM; Yang W; Passini MA; Hester M; Clarke J; Roskelley EM; Treleaven CM; Rizo L; Martin H; Kim SH; Kaspar R; Taksir TV; Griffiths DA; Cheng SH; Shihabuddin LS; Kaspar BK
    Mol Ther; 2008 Jun; 16(6):1056-64. PubMed ID: 18388910
    [TBL] [Abstract][Full Text] [Related]  

  • 43. AAV6-mediated gene silencing fALS short.
    Mandel RJ; Lowenstein PR; Byrne BJ
    Mol Ther; 2011 Feb; 19(2):231-3. PubMed ID: 21289637
    [No Abstract]   [Full Text] [Related]  

  • 44. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 45. Finding a Treatment for ALS - Will Gene Editing Cut It?
    Al-Chalabi A; Brown RH
    N Engl J Med; 2018 Apr; 378(15):1454-1456. PubMed ID: 29641956
    [No Abstract]   [Full Text] [Related]  

  • 46. Symptomatic improvement, increased life-span and sustained cell homing in amyotrophic lateral sclerosis after transplantation of human umbilical cord blood cells genetically modified with adeno-viral vectors expressing a neuro-protective factor and a neural cell adhesion molecule.
    Islamov RR; Rizvanov AA; Mukhamedyarov MA; Salafutdinov II; Garanina EE; Fedotova VY; Solovyeva VV; Mukhamedshina YO; Safiullov ZZ; Izmailov AA; Guseva DS; Zefirov AL; Kiyasov AP; Palotas A
    Curr Gene Ther; 2015; 15(3):266-76. PubMed ID: 25619885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuro-inflammation as a therapeutic target in amyotrophic lateral sclerosis.
    Weydt P; Weiss MD; Möller T; Carter GT
    Curr Opin Investig Drugs; 2002 Dec; 3(12):1720-4. PubMed ID: 12528305
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tandem Delivery of Multiple Therapeutic Genes Using Umbilical Cord Blood Cells Improves Symptomatic Outcomes in ALS.
    Islamov RR; Rizvanov AA; Fedotova VY; Izmailov AA; Safiullov ZZ; Garanina EE; Salafutdinov II; Sokolov ME; Mukhamedyarov MA; Palotás A
    Mol Neurobiol; 2017 Aug; 54(6):4756-4763. PubMed ID: 27495938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
    Sakowski SA; Schuyler AD; Feldman EL
    Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene Therapy for the Treatment of Neurological Disorders: Amyotrophic Lateral Sclerosis.
    McEachin ZT; Donsante A; Boulis N
    Methods Mol Biol; 2016; 1382():399-408. PubMed ID: 26611602
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is There a Role for Exercise in the Management of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis?
    Plowman EK
    J Speech Lang Hear Res; 2015 Aug; 58(4):1151-66. PubMed ID: 26091205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.
    Lewis ME; Vaught JL; Neff NT; Grebow PE; Callison KV; Yu E; Contreras PC; Baldino F
    Ann N Y Acad Sci; 1993 Aug; 692():201-8. PubMed ID: 8215023
    [No Abstract]   [Full Text] [Related]  

  • 53. High throughput drug screening.
    Heemskerk J
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():19-21. PubMed ID: 15512863
    [No Abstract]   [Full Text] [Related]  

  • 54. An updated review on the role of prescribed exercise in the management of Amyotrophic lateral sclerosis.
    Angelini C; Siciliano G
    Expert Rev Neurother; 2021 Aug; 21(8):871-879. PubMed ID: 34237230
    [No Abstract]   [Full Text] [Related]  

  • 55. DNA microarray analysis of transcriptional responses of mouse spinal cords to physical exercise.
    Hashimoto K; Honda A; Hayashi Y; Inuzuka T; Satoh M; Hozumi I
    J Toxicol Sci; 2009 Oct; 34(4):445-8. PubMed ID: 19652469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tele-monitoring of a home-based exercise program in amyotrophic lateral sclerosis: a feasibility study.
    Braga AC; Pinto A; Pinto S; de Carvalho M
    Eur J Phys Rehabil Med; 2018 Jun; 54(3):501-503. PubMed ID: 29363923
    [No Abstract]   [Full Text] [Related]  

  • 57. Prolonged Voluntary Running Negatively Affects Survival and Disease Prognosis of Male SOD1G93A Low-Copy Transgenic Mice.
    Garbugino L; Golini E; Giuliani A; Mandillo S
    Front Behav Neurosci; 2018; 12():275. PubMed ID: 30483078
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cell therapy in amyotrophic lateral sclerosis: a significant step forward.
    Ben-Hur T
    Ann Neurol; 2014 Mar; 75(3):337-8. PubMed ID: 24812695
    [No Abstract]   [Full Text] [Related]  

  • 59. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
    Howe CL; Bergstrom RA; Horazdovsky BF
    Neurology; 2009 Oct; 73(15):1247; author reply 1247-8. PubMed ID: 19822878
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of effective therapy for sporadic ALS.
    Fiala M; Pellegrini M
    Expert Opin Biol Ther; 2015; 15(8):1249. PubMed ID: 26160493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.